# PALL (NCT02808442)

> Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

- Drugs tested: UCART19
- Indication: paediatric relapsed/refractory B-cell acute lymphoblastic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02808442
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Institut de Recherches Internationales Servier
- Conditions: Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
- Interventions: UCART19
- Enrollment: 13
- Primary outcome: Incidence and Severity of Adverse Events

## Indexed commentary on PALL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pall-nct02808442